Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FLKS - Flex Pharma Inc.


Previous close
0.615
0.615   100.000%

Share volume: 0
Last Updated: Fri 19 Jul 2019 10:00:01 PM CEST
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
22%
Profitability 25%
Dept financing 3%
Liquidity 60%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.62
P/E Ratio 
N/A
DAY RANGE
$0.62 - $0.62
EPS 
-$0.46
52 WEEK RANGE
$0.26 - $1.49
52 WEEK CHANGE
-$28.43
MARKET CAP 
11.112 M
YIELD 
N/A
SHARES OUTSTANDING 
18.069 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,459,242
AVERAGE 30 VOLUME 
$1,948,387
Company detail
CEO: William K. McVicar
Region: US
Website: http://www.flex-pharma.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.

Recent news